Abstract
Summary:
Ideal targets for chimeric antigen receptor T-cell therapy for acute myeloid leukemia (AML) remain elusive. In this issue of Blood Cancer Discovery, Richards and colleagues explore CD93 as a potential AML target antigen, and devise an approach to mitigate “on-target/off-cancer toxicity.”
See related article by Richards et al., p. 648.
©2021 American Association for Cancer Research
2021
American Association for Cancer Research
You do not currently have access to this content.